<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="7857" end="7862" sStart="7697" offset="160" sid="r7.1.use.v.0643" wn="1" wnkey="use%2:34:01::" text="The effect of CPT on the production of types I, III, and VI collagen by 11 pairs of SSc and normal dermal fibroblasts was examined by ELISA using fibroblast cell and matrix layers (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="5434" end="5438" sStart="null" offset="87" sid="r7.1.use.v.0111" wn="1" wnkey="use%2:34:01::" text="To determine the effect of CPT on newly synthesized collagenous proteins, we used an established method of metabolic labeling with [ 3H]proline followed by SDS-PAGE electrophoresis [ 22]." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="17178" end="17186" sStart="null" offset="65" sid="r8.suggest.v.0368" wn="3" wnkey="suggest%2:32:02::" text="The inhibitory effect of CPT on collagen gene expression suggests that Topo I inhibitors may be an effective treatment for limiting fibrosis in SSc patients." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="20408" end="20419" sStart="null" offset="315" sid="r11.recommend.v.0538" wn="1" wnkey="recommend%2:32:01::" text="Deposition of collagen and elastin in cell and matrix layers was determined by solid-phase ELISA with antibodies against goat anti-collagen I (Chemicon), mouse anti-collagen III (Telios), mouse anti-collagen VI (Telios), or mouse anti-elastin (Sigma), at dilutions recommended by the manufacturers." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="5293" end="5304" sStart="null" offset="351" sid="r11.recommend.v.0537" wn="1" wnkey="recommend%2:32:01::" text="Collagen and elastin deposition in cell and matrix layers was determined by solid-phase ELISA with antibodies against goat anti-collagen I (Chemicon, Temecula, CA, USA), mouse anti-collagen III (Telios, San Diego, CA, USA), mouse anti-collagen VI (Telios), or mouse anti-elastin (Sigma), at dilutions recommended by the manufacturers." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="11255" end="11261" sStart="null" offset="98" sid="r9.level.n.0154" wn="1" wnkey="level%1:07:00::" text="CPT treatment resulted in a dose-dependent decrease of COL1A2 mRNA expression levels in SSc and healthy control fibroblasts as demonstrated by northern blot analysis." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="8226" end="8233" sStart="null" offset="105" sid="r10.control.n.0751" wn="4" wnkey="control%1:09:02::" text="Although CPT at 10 -7mol/l decreased collagen production more in SSc than in healthy control fibroblasts (by, respectively, 68% and 48% for type I, 38% and 15% for type II, and 21% and 7% for type III) (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="18773" end="18780" sStart="null" offset="0" sid="r10.control.n.0328" wn="4" wnkey="control%1:09:02::" text="Control dermal fibroblasts, from healthy donors matched for race, age, and gender with donors of SSc cell lines, were obtained by skin biopsy within several days of the SSc biopsy and were processed in parallel." />
    <s path="[OANC]/data/written_2/technical/biomed/ar321.anc" start="8822" end="8829" sStart="null" offset="194" sid="r10.control.n.0850" wn="4" wnkey="control%1:09:02::" text="To assess the effect of CPT on production of other extracellular matrix proteins, the effect on elastin was measured by ELISA: no effect was found in either SSc or control fibroblasts (Fig." />
  </sentences>
</list>